Adjunctive povidone-iodine for Acanthamoeba keratitis: a randomized trial
Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)
DOI: 10.1128/aac.01512-25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Revathi Rajaraman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cornea Department, Aravind Eye Hospital, Coimbatore, India. Hauptthemen laut MEDLINE: Povidone-Iodine, Acanthamoeba Keratitis, Acanthamoeba, Anti-Infective Agents, Local. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Research to Prevent Blindness, All May See Foundation.
Abstract (Originalsprache)
The aim of this study was to determine the antiamoebic efficacy of povidone-iodine when used as an adjunct to topical biguanide therapy for Acanthamoeba keratitis. Patients with smear- or culture-positive Acanthamoeba keratitis received topical chlorhexidine 0.04%, half-hourly for 2 days, then hourly for days 3–6, then eight times per day for days 7–28. Participants were randomized in a 1:1 ratio to receive either adjunctive topical povidone-iodine at the same frequency as chlorhexidine or no additional therapy (i.e., control group). Povidone-iodine was initially administered as a 2.5% solution but was reduced to a 1% solution after several reports of intolerance. The primary outcome was Acanthamoeba growth from the culture of corneal scrapings at 1, 2, and 4 weeks after randomization, as assessed by laboratory staff masked to treatment allocation. Of 49 patients enrolled, 25 were randomized to adjunctive povidone-iodine (mean age 48 [SD 16] years; 32% female) and 24 to control (mean age 43 [15] years; 33% female). Four (16%) participants discontinued 2.5% povidone-iodine prematurely due to intolerance. The proportion of participants with a positive culture during the initial 4 weeks of antiamoebic treatment was not significantly different in the povidone-iodine group (6/18 [33%] at 4 weeks) and control group (5/16 [31%] at 4 weeks) (RR 0.90, 95%CI: 0.35–2.29; P = 0.82). When used as an adjunctive to standard biguanide therapy, povidone-iodine did not markedly accelerate the clearance of Acanthamoeba organisms from the corneal surface over the initial month of therapy. This study is registered with ClinicalTrials.gov as NCT03484507 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cornea Department, Aravind Eye Hospital, Coimbatore, India.
- Francis I Proctor Foundation, University of California, San Francisco, California, USA.
- Department of Cornea and Refractive Surgery, Aravind Eye Hospital, Madurai, India.
- Department of Microbiology, Aravind Eye Hospital, Madurai, India.
- Department of Microbiology, Aravind Eye Hospital, Coimbatore, India.
- Department of Ophthalmology, University of California, San Francisco, California, USA.
ORCID-Profile: Travis C Porco, Thomas M Lietman, Jeremy D Keenan
Förderung
- NEI NIH HHS
- Research to Prevent Blindness
- All May See Foundation
- Peierls Foundation
- National Eye Institute
Zitieren
APA
Rajaraman, R., Kassaye, I., Sharma, S. S., Prajna, N. V., Lalitha, P., Panigrahi, A., Rammohan, R., Aromin, K. M., Cook, C., Porco, T. C., Lietman, T. M., Seitzman, G. D., & Keenan, J. D. (2026). Adjunctive povidone-iodine for Acanthamoeba keratitis: a randomized trial. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01512-25
Vancouver
Rajaraman R, Kassaye I, Sharma SS, Prajna NV, Lalitha P, Panigrahi A, et al. Adjunctive povidone-iodine for Acanthamoeba keratitis: a randomized trial. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01512-25
BibTeX
@article{Rajaraman2026,
author = {Rajaraman, Revathi and Kassaye, Isabell and Sharma, Sankalp S and Prajna, N Venkatesh and Lalitha, Prajna and Panigrahi, Arunkumar and Rammohan, Ram and Aromin, Krisianne M and Cook, Catherine and Porco, Travis C and Lietman, Thomas M and Seitzman, Gerami D and Keenan, Jeremy D},
title = {Adjunctive povidone-iodine for Acanthamoeba keratitis: a randomized trial},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {5},
doi = {10.1128/aac.01512-25}
}
EUVIMED